|
1
|
Tavassoli FA and Devilee P: Pathology and
Genetics. Tumours of the Breast and Female Genital organs. IARC
Press. (Lyon). 2003.
|
|
2
|
Prat J: Ovarian carcinomas: Five distinct
diseases with different origins, genetic alterations, and
clinicopathological features. Virchows Arch. 460:237–249. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Micci F, Haugom L, Ahlquist T, Andersen
HK, Abeler VM, Davidson B, Trope CG, Lothe RA and Heim S: Genomic
aberrations in borderline ovarian tumors. J Transl Med. 8:212010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Buy JN and Ghossain M: Sex cord-stromal
tumors. Gynecological Imaging: A Reference Guide to Diagnosis.
Springer-Verlag. (Berlin, Heidelberg). 329–375. 2013. View Article : Google Scholar
|
|
5
|
Micci F, Haugom L, Abeler VM, Tropé CG,
Danielsen HE and Heim S: Consistent numerical chromosome
aberrations in thecofibromas of the ovary. Virchows Arch.
452:269–276. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Micci F, Haugom L, Abeler VM, Davidson B,
Tropé CG and Heim S: Genomic profile of ovarian carcinomas. BMC
Cancer. 14:3152014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Agostini A, Panagopoulos I, Andersen HK,
Johannesen LE, Davidson B, Tropé CG, Heim S and Micci F: HMGA2
expression pattern and TERT mutations in tumors of the vulva. Oncol
Rep. 33:2675–2680. 2015.PubMed/NCBI
|
|
8
|
Korbie DJ and Mattick JS: Touchdown PCR
for increased specificity and sensitivity in PCR amplification. Nat
Protoc. 3:1452–1456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Smith E, Jones ME and Drew PA:
Quantitation of DNA methylation by melt curve analysis. BMC Cancer.
9:1–12. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Heidenreich B, Rachakonda PS, Hemminki K
and Kumar R: TERT promoter mutations in cancer development. Curr
Opin Genet Dev. 24:30–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chiappetta G, Avantaggiato V, Visconti R,
Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti
V, Santoro M, et al: High level expression of the HMGI (Y) gene
during embryonic development. Oncogene. 13:2439–2446.
1996.PubMed/NCBI
|
|
12
|
Rogalla P, Drechsler K, Frey G, Hennig Y,
Helmke B, Bonk U and Bullerdiek J: HMGI-C expression patterns in
human tissues. Implications for the genesis of frequent mesenchymal
tumors. Am J Pathol. 149:775–779. 1996.PubMed/NCBI
|
|
13
|
Pallante P, Sepe R, Puca F and Fusco A:
High mobility group A (HMGA) proteins as tumor markers. Front Med
(Lausanne). 2:152015.PubMed/NCBI
|
|
14
|
Wu J and Wei JJ: HMGA2 and high-grade
serous ovarian carcinoma. J Mol Med (Berl). 91:1155–1165. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morishita A, Zaidi MR, Mitoro A,
Sankarasharma D, Szabolcs M, Okada Y, D'Armiento J and Chada K:
HMGA2 is a driver of tumor metastasis. Cancer Res. 73:4289–4299.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hetland TE, Holth A, Kærn J, Flørenes VA,
Tropé CG and Davidson B: HMGA2 protein expression in ovarian serous
carcinoma effusions, primary tumors, and solid metastases. Virchows
Arch. 460:505–513. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schoenmakers EF, Wanschura S, Mols R,
Bullerdiek J, Van den Berghe H and Van de Ven WJ: Recurrent
rearrangements in the high mobility group protein gene, HMGI-C, in
benign mesenchymal tumours. Nat Genet. 10:436–444. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Geurts JM, Schoenmakers EF and Van de Ven
WJ: Molecular characterization of a complex chromosomal
rearrangement in a pleomorphic salivary gland adenoma involving the
3′-UTR of HMGIC. Cancer Genet Cytogenet. 95:198–205. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mine N, Kurose K, Nagai H, Doi D, Ota Y,
Yoneyama K, Konishi H, Araki T and Emi M: Gene fusion involving
HMGIC is a frequent aberration in uterine leiomyomas. J Hum Genet.
46:408–412. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kazmierczak B, Meyer-Bolte K, Tran KH,
Wöckel W, Breightman I, Rosigkeit J, Bartnitzke S and Bullerdiek J:
A high frequency of tumors with rearrangements of genes of the
HMGI(Y) family in a series of 191 pulmonary chondroid hamartomas.
Genes Chromosomes Cancer. 26:125–133. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He X, Yang J, Zhang Q, Cui H and Zhang Y:
Shortening of the 3′ untranslated region: An important mechanism
leading to overexpression of HMGA2 in serous ovarian cancer. Chin
Med J (Engl). 127:494–499. 2014.PubMed/NCBI
|
|
22
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang DS, Wang Z, He XJ, Diplas BH, Yang
R, Killela PJ, Meng Q, Ye ZY, Wang W, Jiang XT, et al: Recurrent
TERT promoter mutations identified in a large-scale study of
multiple tumour types are associated with increased TERT expression
and telomerase activation. Eur J Cancer. 51:969–976. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vinagre J, Almeida A, Pópulo H, Batista R,
Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al:
Frequency of TERT promoter mutations in human cancers. Nat Commun.
4:21852013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang HN, Chiang YC, Cheng WF, Chen CA,
Lin MC and Kuo KT: Molecular alterations in endometrial and ovarian
clear cell carcinomas: Clinical impacts of telomerase reverse
transcriptase promoter mutation. Mod Pathol. 28:303–311. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Havik AB, Lind GE, Honne H, Meling TR,
Scheie D, Hall KS, van den Berg E, Mertens F, Picci P, Lothe RA, et
al: Sequencing IDH1/2 glioma mutation hotspots in gliomas and
malignant peripheral nerve sheath tumors. Neuro Oncol. 16:320–322.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Patel KP, Barkoh BA, Chen Z, Ma D, Reddy
N, Medeiros LJ and Luthra R: Diagnostic testing for IDH1 and IDH2
variants in acute myeloid leukemia an algorithmic approach using
high-resolution melting curve analysis. J Mol Diagn. 13:678–686.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wagner K, Damm F, Göhring G, Görlich K,
Heuser M, Schäfer I, Ottmann O, Lübbert M, Heit W, Kanz L, et al:
Impact of IDH1 R132 mutations and an IDH1 single nucleotide
polymorphism in cytogenetically normal acute myeloid leukemia: SNP
rs11554137 is an adverse prognostic factor. J Clin Oncol.
28:2356–2364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Margison GP and Santibáñez-Koref MF:
O6-alkylguanine-DNA alkyltransferase: Role in carcinogenesis and
chemotherapy. Bioessays. 24:255–266. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Håvik AB, Brandal P, Honne H, Dahlback HS,
Scheie D, Hektoen M, Meling TR, Helseth E, Heim S, Lothe RA and
Lind GE: MGMT promoter methylation in gliomas-assessment by
pyrosequencing and quantitative methylation-specific PCR. J Transl
Med. 10:362012. View Article : Google Scholar : PubMed/NCBI
|
